Opinion of the Transparency Council – valgancyclovir

At its meeting on 29 July 2024, the Transparency Council adopted opinion No. 116/2024 on the on the inclusion in the reimbursement of medicines containing the active substance valgancyclovir as regards indications for use or dosage or route of administration other than those specified in the summary of product characteristics, i.e. cytomegalovirus infection after organ or bone marrow transplantation – treatment; Epstein-Barr virus infection after organ or bone marrow transplantation – treatment

Publication on the list of opinions on active substances for off-label indications >>